Daratumumab Increases Listeria Susceptibility

Patients with multiple myeloma who are receiving daratumumab (Darzalex®, Janssen) have an increased susceptibility to listeriosis, a potentially deadly infection by Listeria monocytogenes , a gram-positive bacterium to which individuals with weakened immune systems are susceptible. Daratumumab, a CD38 monoclonal antibody, is effective against multiple myeloma because CD38 is strongly expressed in multiple myeloma cells. However, activated macrophages also express CD38. It seems to be an importan...
Continue reading

Managing Ibrutinib-Related Hypertension in B-Cell Malignancies: Daniel Addison, MD

​ Ibrutinib is an effective treatment for several B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it can cause cardiotoxicity. Under the direction of Daniel Addison, MD, a team of researchers recently found that hypertension caused or worsened by treatment with ibrutinib results in a greater than two-fold increased risk of major adverse cardiovascular events . In this interview with i3 Health, Dr. Addison discusses wh...
Continue reading

No Long-Term “Chemo Brain” Impact in Testicular Cancer

Cognitive changes have been associated with various cancer treatments. In studies, between 17% and 75% of breast cancer survivors have reported cognitive deficits after chemotherapy. Commonly known as "chemo brain," these symptoms have had reported durations of up to 20 years after receipt of breast cancer treatment. Fortunately, this is not the case for patients with testicular cancer: a new study shows no long-term cognitive impairment following chemotherapy. The prospective study, p...
Continue reading

Ibrutinib Increases Hypertension and Cardiovascular Risk

For patients with B-cell malignancies, the hypertension caused or worsened by treatment with ibrutinib results in a two-fold increased risk of major adverse cardiovascular events, report researchers at The Ohio State University. Ibrutinib can be highly effective against B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it also is associated with cardiotoxicity. Severe hypertension has been reported, but "the long-term inci...
Continue reading

Epidermal Growth Factor Ointment for Skin Toxicities: An Interview With Sung Yong Oh, MD, PhD

By inhibiting epidermal growth factor receptor (EGFR) signaling pathways, EGFR inhibitors have shown efficacy in the treatment of a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. However, most patients who receive EGFR inhibitors develop adverse skin events, such as acneiform rash, xerosis, paronychial inflammation, pruritis, photosensitivity, and hair and eyelash alteration. If not properly managed, these toxicities can lead to physic...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.